Search

Displaying results 341 - 350 of 4584 in total
  1. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    [A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.

  2. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [ribavirin] depending on the level of liver damage or cirrhosis [FDA Label]. … Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon- and ribavirin-based regimens, which were limited by infusion site reactions, reduced blood

  3. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    combination with fluticasone propionate as a nasal spray marketed under the trade name Dymista™, which is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older

  4. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.

  5. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Studies demonstrated that reslizumab was not effective in various asthma outcomes in patients without eosinophilia [A31577]. Reslizumab was developed by Teva Pharmaceuticals. … Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion.

  6. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients

  7. Drug

    Succinylcholine

    go.drugbank.com/drugs/DB00202
    ApprovedInvestigational

    Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups.

  8. Drug

    Naratriptan

    go.drugbank.com/drugs/DB00952
    Approved

    Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.

  9. Drug

    Ammonium chloride

    go.drugbank.com/drugs/DB06767
    ApprovedInvestigationalVet approved

    Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.

  10. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.